Cancer treatment group Nanobiotix (EPA:NANO) has reported ‘excellent’ results from an early stage trial of its nanoparticle technology in liver cancer sufferers.
The aim with trial with NBTXR3, one of seven Nanobiotix has ongoing in various types of cancer, is to amplify the energy dose within the tumour in the liver to improve the result from treatment.
The nanopaticles were administered by intra-tumoural (IT) injection and activated by high precision radiation therapy.
Patients received a NBTXR3 dose equivalent to 10% of the tumour volume. The trial showed a good safety profile with no adverse events and no leakage on the healthy surrounding tissue.
Next steps will to increase the dosage to test for safety and tolerance.
Liver cancer is one of the hardest forms of the disease to treat as although it responds well to radiation therapy delivering the radioactive dose is complex.
Elsa Borghi, Nanobiotix’s chief medical officer, said: “At this stage, the safety and feasibility data of NBTXR3 in liver cancers are excellent.
“Observations are similar to the results of our more advanced trials: Soft Tissue Sarcoma and Head and Neck cancers.
“This is significant because these trials cover very different patient and disease profiles.
“Based on the information gathered to date, we anticipate that by the end of this phase, we will have identified the appropriate conditions to use NBTXR3 in these patients populations.
“Once again, all transferability data show the potential of broad applicability of NBTXR3 for use with radiotherapy in the treatment of solid tumors.”
Nanobiotix’s nanopaticle treatment, NBTXR3 is injected into cancerous tumours where it absorbs the ionizing radiation delivered by radiotherapy and magnifies its effect locally. This shrinks the tumour making it easier to remove during surgery.